2138.HK
EC Healthcare [2138.HK] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
2138.HK Stock Summary
Top 10 Correlated ETFs
2138.HK
Top 10 Correlated Stocks
2138.HK
In the News
2138.HK Financial details
Company Rating
Buy
Market Cap
1.45B
Income
113.6M
Revenue
7.47B
Book val./share
1.59
Cash/share
0.57
Dividend
0.05
Dividend %
3.24%
Employees
2.72K
Optionable
No
Shortable
Yes
Earnings
26 Jun 2024
P/E
57.14
Forward P/E
-
PEG
-12.58
P/S
0.61
P/B
0.91
P/C
2.09
P/FCF
16.24
Quick Ratio
0.43
Current Ratio
0.85
Debt / Equity
0.57
LT Debt / Equity
0.28
-
-
EPS (TTM)
0.09
EPS next Y
-
EPS next Q
-
EPS this Y
-65.29%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-30.73%
Revenue last 5Y
15.91%
Revenue Q/Q
7.02%
EPS Q/Q
-163.64%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-50%
Inst Own
0%
Inst Trans
0.67%
ROA
1%
ROE
2%
ROC
0.02%
Gross Margin
32%
Oper. Margin
2%
Profit Margin
1%
Payout
398%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.12-6.12
52W High
-80.17%
52W Low
+19%
RSI
42
Rel Volume
0.43
Avg Volume
3.03M
Volume
1.31M
Perf Week
-5.56%
Perf Month
-4.8%
Perf Quarter
-51.82%
Perf Half Y
-55.26%
-
-
-
-
Beta
1.306
-
-
Volatility
0.02%, 0.09%
Prev Close
-4.03%
Price
1.19
Change
-4.03%
2138.HK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.88 | 1.98 | 2.03 | 2.53 | 3.28 | |
| Net income per share | 0.37 | 0.29 | 0.19 | 0.17 | 0.06 | |
| Operating cash flow per share | 0.24 | 0.58 | 0.6 | 0.52 | 0.52 | |
| Free cash flow per share | -0.04 | 0.51 | 0.46 | 0.3 | 0.17 | |
| Cash per share | 0.4 | 0.64 | 0.91 | 0.76 | 0.62 | |
| Book value per share | 1.06 | 1.02 | 1.24 | 1.63 | 1.57 | |
| Tangible book value per share | 0.99 | 0.75 | 0.16 | 0.21 | 0.19 | |
| Share holders equity per share | 1.06 | 1.02 | 1.24 | 1.63 | 1.57 | |
| Interest debt per share | 0.56 | 0.75 | 0.74 | 0.53 | 0.92 | |
| Market cap | 5.66B | 3.35B | 6.96B | 9.61B | 7.4B | |
| Enterprise value | 5.83B | 3.55B | 7.06B | 9.69B | 8.22B | |
| P/E ratio | 15.67 | 11.69 | 36.09 | 48.68 | 106.27 | |
| Price to sales ratio | 3.05 | 1.72 | 3.35 | 3.29 | 1.91 | |
| POCF ratio | 23.73 | 5.83 | 11.29 | 15.93 | 12.17 | |
| PFCF ratio | -149.81 | 6.64 | 14.89 | 28.01 | 37.8 | |
| P/B Ratio | 5.43 | 3.34 | 5.49 | 5.11 | 3.99 | |
| PTB ratio | 5.43 | 3.34 | 5.49 | 5.11 | 3.99 | |
| EV to sales | 3.15 | 1.82 | 3.39 | 3.32 | 2.12 | |
| Enterprise value over EBITDA | 11.64 | 6.03 | 14.21 | 12.69 | 11.54 | |
| EV to operating cash flow | 24.47 | 6.18 | 11.45 | 16.06 | 13.52 | |
| EV to free cash flow | -154.52 | 7.03 | 15.1 | 28.23 | 42 | |
| Earnings yield | 0.06 | 0.09 | 0.03 | 0.02 | 0.01 | |
| Free cash flow yield | -0.01 | 0.15 | 0.07 | 0.04 | 0.03 | |
| Debt to equity | 0.52 | 0.72 | 0.58 | 0.3 | 0.55 | |
| Debt to assets | 0.23 | 0.28 | 0.19 | 0.11 | 0.18 | |
| Net debt to EBITDA | 0.35 | 0.34 | 0.2 | 0.1 | 1.15 | |
| Current ratio | 1.25 | 0.92 | 1.03 | 1.01 | 0.78 | |
| Interest coverage | 160.18 | 18.98 | 7.07 | 6.27 | 1.76 | |
| Income quality | 0.66 | 2 | 3.2 | 3.06 | 8.73 | |
| Dividend Yield | 0.02 | 0.1 | 0.02 | 0.03 | 0.02 | |
| Payout ratio | 0.27 | 1.2 | 0.59 | 1.38 | 1.69 | |
| Sales general and administrative to revenue | 0.12 | 0.1 | 0.06 | 0.06 | 0.06 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.08 | 0.17 | 0.39 | 0.43 | 0.39 | |
| Capex to operating cash flow | -1.16 | -0.12 | -0.24 | -0.43 | -0.68 | |
| Capex to revenue | -0.15 | -0.04 | -0.07 | -0.09 | -0.11 | |
| Capex to depreciation | -4.47 | -0.28 | -0.48 | -0.6 | -0.7 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0 | 0.01 | 0.02 | |
| Graham number | 2.96 | 2.58 | 2.29 | 2.51 | 1.44 | |
| ROIC | 0.2 | 0.15 | 0.07 | 0.1 | 0.03 | |
| Return on tangible assets | 0.17 | 0.13 | 0.08 | 0.07 | 0.02 | |
| Graham Net | -0.69 | -0.56 | -1.04 | -1.26 | -1.85 | |
| Working capital | 279.77M | -90M | 34.33M | 9.39M | -375.73M | |
| Tangible asset value | 977.3M | 743.57M | 164.45M | 240.47M | 221.43M | |
| Net current asset value | 223.61M | -406.44M | -808.14M | -1.14B | -1.84B | |
| Invested capital | 0.52 | 0.72 | 0.58 | 0.3 | 0.55 | |
| Average receivables | 86.67M | 164.18M | 202.95M | 182.66M | 213.58M | |
| Average payables | 15.66M | 28.8M | 41.19M | 60.93M | 72.65M | |
| Average inventory | 41.76M | 55.86M | 49.58M | 70.31M | 93.99M | |
| Days sales outstanding | 20.62 | 41.9 | 31.97 | 22.89 | 22.99 | |
| Days payables outstanding | 9.07 | 10.04 | 10.91 | 12.67 | 7.99 | |
| Days of inventory on hand | 21.58 | 16.76 | 9.24 | 17.03 | 9.91 | |
| Receivables turnover | 17.7 | 8.71 | 11.42 | 15.95 | 15.88 | |
| Payables turnover | 40.26 | 36.35 | 33.46 | 28.81 | 45.66 | |
| Inventory turnover | 16.92 | 21.78 | 39.49 | 21.43 | 36.84 | |
| ROE | 0.35 | 0.29 | 0.15 | 0.1 | 0.04 | |
| Capex per share | -0.28 | -0.07 | -0.15 | -0.23 | -0.35 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q2
| Metric | History | 2021-09-30 | 2022-03-31 | 2022-09-30 | 2023-03-31 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.28 | 1.11 | 1.61 | 1.67 | 1.79 | |
| Net income per share | 0.14 | 0.03 | 0.07 | -0.01 | 0.01 | |
| Operating cash flow per share | 0.34 | 0.17 | 0.14 | 0.37 | 0.25 | |
| Free cash flow per share | 0.34 | -0.03 | 0.14 | 0.02 | 0.25 | |
| Cash per share | 1.31 | 0.66 | 0.62 | 0.61 | 0.57 | |
| Book value per share | 1.87 | 1.42 | 1.65 | 1.56 | 1.59 | |
| Tangible book value per share | 0.77 | 0.18 | 0.22 | 0.19 | 0.03 | |
| Share holders equity per share | 1.87 | 1.42 | 1.65 | 1.56 | 1.59 | |
| Interest debt per share | 0.5 | 0.44 | 0.82 | 0.89 | 0.94 | |
| Market cap | 11.89B | 11.07B | 5.75B | 7.43B | 3.6B | |
| Enterprise value | 11.21B | 11.15B | 6.33B | 8.25B | 4.5B | |
| P/E ratio | 18.55 | 74.24 | 17.96 | -178.77 | 135.43 | |
| Price to sales ratio | 8.24 | 7.5 | 3.04 | 3.75 | 1.7 | |
| POCF ratio | 30.94 | 50.53 | 34.24 | 16.88 | 12.35 | |
| PFCF ratio | 30.94 | -269.4 | 34.24 | 253.26 | 12.35 | |
| P/B Ratio | 5.64 | 5.89 | 2.96 | 4.01 | 1.92 | |
| PTB ratio | 5.64 | 5.89 | 2.96 | 4.01 | 1.92 | |
| EV to sales | 7.76 | 7.55 | 3.35 | 4.16 | 2.12 | |
| Enterprise value over EBITDA | 26.77 | 32.54 | 16.57 | 24.97 | 12.33 | |
| EV to operating cash flow | 29.16 | 50.87 | 37.71 | 18.74 | 15.42 | |
| EV to free cash flow | 29.16 | -271.21 | 37.71 | 281.28 | 15.42 | |
| Earnings yield | 0.01 | 0 | 0.01 | 0 | 0 | |
| Free cash flow yield | 0.03 | 0 | 0.03 | 0 | 0.08 | |
| Debt to equity | 0.26 | 0.3 | 0.48 | 0.55 | 0.57 | |
| Debt to assets | 0.12 | 0.11 | 0.18 | 0.18 | 0.19 | |
| Net debt to EBITDA | -1.63 | 0.22 | 1.52 | 2.49 | 2.46 | |
| Current ratio | 1.56 | 1.01 | 1.04 | 0.78 | 0.81 | |
| Interest coverage | 12.58 | 3.03 | 2.94 | 0.77 | 1.53 | |
| Income quality | 2.4 | 5.88 | 2.1 | -42.37 | 43.88 | |
| Dividend Yield | 0 | 0.02 | 0 | 0.02 | 0 | |
| Payout ratio | 0 | 7.29 | 0 | -11.36 | 0 | |
| Sales general and administrative to revenue | 0.11 | 0.11 | 0.05 | 0.12 | 0.05 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.36 | 0.43 | 0.41 | 0.39 | 0.43 | |
| Capex to operating cash flow | 0 | -1.19 | 0 | -0.93 | 0 | |
| Capex to revenue | 0 | -0.18 | 0 | -0.21 | 0 | |
| Capex to depreciation | 0 | -1.07 | 0 | -1.37 | 0 | |
| Stock based compensation to revenue | 0 | 0.02 | 0 | 0.03 | 0 | |
| Graham number | 2.44 | 0.95 | 1.59 | 0.56 | 0.45 | |
| ROIC | 0.07 | 0.03 | 0.02 | 0 | 0.01 | |
| Return on tangible assets | 0.05 | 0.01 | 0.03 | 0 | 0 | |
| Graham Net | -0.34 | -1.09 | -1.57 | -1.85 | -1.85 | |
| Working capital | 705.08M | 9.39M | 47.45M | -375.73M | -316.41M | |
| Tangible asset value | 869.91M | 240.47M | 265.14M | 221.43M | 33.21M | |
| Net current asset value | -78.48M | -1.14B | -1.48B | -1.84B | -1.79B | |
| Invested capital | 0.26 | 0.3 | 0.48 | 0.55 | 0.57 | |
| Average receivables | 193.83M | 194.26M | 215.25M | 245.74M | 276.61M | |
| Average payables | 44.13M | 58.4M | 70.32M | 67.77M | 71.11M | |
| Average inventory | 49.51M | 80.3M | 93.9M | 86.8M | 100.81M | |
| Days sales outstanding | 12.81 | 11.17 | 11.76 | 11.08 | 13.12 | |
| Days payables outstanding | 3.79 | 5.74 | 3.87 | 3.76 | 3.68 | |
| Days of inventory on hand | 5.42 | 7.72 | 5.13 | 4.66 | 5.86 | |
| Receivables turnover | 7.03 | 8.06 | 7.65 | 8.12 | 6.86 | |
| Payables turnover | 23.73 | 15.68 | 23.26 | 23.95 | 24.43 | |
| Inventory turnover | 16.59 | 11.66 | 17.55 | 19.32 | 15.36 | |
| ROE | 0.08 | 0.02 | 0.04 | -0.01 | 0 | |
| Capex per share | 0 | -0.2 | 0 | -0.35 | 0 |
2138.HK Frequently Asked Questions
What is EC Healthcare stock symbol ?
EC Healthcare is a HK stock and trading under the symbol 2138.HK
What is EC Healthcare stock quote today ?
EC Healthcare stock price is $1.19 today.
Is EC Healthcare stock public?
Yes, EC Healthcare is a publicly traded company.
Company Profile
- Volume Average 3.03M
- Market Capitalization 1.45B
- Employee 2.72K
- CEO Mr. Lyn Wade Lu
- Headquarters Mong Kok,HK
- IPO Date 2016-03-11
-
Website
https://www.echealthcare.com 
EC Healthcare, an investment holding company, engages in the provision of medical and healthcare services in Hong Kong, Macau, and the People's Republic of China. The company operates through three segments: Medical, Aesthetic Medical and Beauty and Wellness, and Others. It provides quasi-medical, beauty and wellness, medical imaging, medical surgery, aesthetic medical beauty, aesthetic medical, dental, hair treatment, vaccine, chiropractic, psychological, and orthopedics services. It also offers administrative, management, laboratory testing, performance marketing, marketing, and travel agency services; sells beauty and skincare products; operates in healthcare machines and property investment holding businesses; and provides multi-channel networking and related services, and veterinary services. The company offers products and services primarily under private-label brands, such as PRODERMA LAB, Swissline, Suissebeaute, and re:HEALTH. The company was formerly known as Union Medical Healthcare Limited and changed its name to EC Healthcare in April 2021. EC Healthcare was founded in 2005 and is headquartered in Mong Kok, Hong Kong.
